Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01443858 · ClinicalTrials.gov registry record · Phase 2
Meclizine as a Potential Smoking Cessation Treatment
A Phase 2 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 146
- Enrollment target
NCT01443858 is a Phase 2 study that has completed, run by Duke University. The registered enrollment target is 146 participants.
The verdict
NCT01443858, a Phase 2 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 146 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether meclizine, an antihistamine used to prevent or treat motion sickness, can help smokers quit smoking. This study will also investigate the potential relationship between genes you have inherited and success in quitting smoking.
Interventions
- DRUG Placebo
- DRUG Nicotine Patch
- DRUG Meclizine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2011-08 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01443858
The ClinicalTrials.gov registry entry for NCT01443858 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 146 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01443858 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01443858 about?
NCT01443858 is a clinical study titled "Meclizine as a Potential Smoking Cessation Treatment". The purpose of this study is to evaluate whether meclizine, an antihistamine used to prevent or treat motion sickness, can help smokers quit smoking. This study will also investigate the potential relationship between genes you have inherited and success in quitting smoking.
What is the current status of trial NCT01443858?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 146 participants. The study started on 2011-08. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01443858?
The interventions under investigation include: Placebo (DRUG), Nicotine Patch (DRUG), Meclizine (DRUG).
Who is sponsoring clinical trial NCT01443858?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.